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Edited by Lukas HuberAbstract Various molecular mechanisms of unconventional
secretion of ﬁbroblast growth factor 2 and galectin-1 have been
proposed. A non-vesicular pathway that is based on direct trans-
location across the plasma membrane has been described. In
other studies, however, release into the extracellular space of
cell-derived vesicles was implicated in both FGF-2 and Gal-1
secretion. Such vesicles were proposed to originate either from
plasma membrane shedding or by the release of exosomes.
Employing an inhibitor of plasma membrane blebbing and based
on a quantitative biochemical analysis of cell culture superna-
tants for vesicles potentially carrying FGF-2 or Gal-1, we dem-
onstrate that both FGF-2 and Gal-1 are not exported by
shedding of plasma membrane-derived vesicles.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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export; Fibroblast growth factor 2; Galectin-11. Introduction
FGF-2 is a growth factor that transmits proangiogenic sig-
nals through the formation of a ternary complex with heparan
sulfate proteoglycans and high aﬃnity FGF receptors [1,2]. It
is generally accepted that externalization of FGF-2 from cells
does not involve the classical ER/Golgi-dependent secretory
pathway [3,4], a feature FGF-2 shares with other secretory
proteins such as galectin-1 (Gal-1) [3–5]. FGF-2 secretion,
however, does not result in the release of a soluble form into
the extracellular space but rather in a cell-surface-associated
population of FGF-2 molecules that remain bound to heparan
sulfate proteoglycans [6–9].
Both vesicular and non-vesicular mechanisms of unconven-
tional protein secretion have been proposed [10]. Using an
in vitro system employing plasma membrane inside-out vesi-
cles, it has been shown that FGF-2 can translocate across plas-
ma membranes [11]. Consistently, a direct role of heparan
sulfate proteoglycans in FGF-2 secretion could be established
[9]. The combined data led to the proposal of a secretion model
in which FGF-2 is initially recruited to the inner leaﬂet of plas-
ma membranes followed by membrane translocation in a*Corresponding author.
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doi:10.1016/j.febslet.2008.03.024HSPG-dependent manner [12]. The idea of cell-surface recep-
tors forming a molecular trapping mechanism for unconven-
tional secretory lectins could be extended to galectin-1 [13].
Thus, for both FGF-2 and Gal-1, non-vesicular pathways of
secretion have been described that rely on direct protein trans-
location across plasma membranes [12].
In other studies, two additional modes of externalization of
FGF-2 have been proposed. On the one hand, experimental
conditions resulting in extensive plasma membrane blebbing
concomitant with shedding of vesicles into the extracellular
space have been implicated in FGF-2 secretion [14–16]. On
the other hand, it has been reported that the expression of
the Epstein-barr virus protein LMP1 results in an increased
rate of FGF-2 secretion [17]. Recently, these studies have been
extended in that LMP-1-dependent release of FGF-2 was pro-
posed to involve exosomes derived from multi-vesicular bodies
[18]. Thus, in both cases, cell-derived membrane vesicles have
been implicated in the overall process of FGF-2 secretion.
Here we made use of a well-characterized model system
based on CHO cells in which eﬃcient export of FGF-2 and
Gal-1 has been demonstrated [6,7,9,13,19,20]. While exposing
substantial amounts of FGF-2 and Gal-1 on their cell surfaces,
we demonstrate that these cells do not release vesicles into the
cell culture supernatant carrying FGF-2 or Gal-1. Further-
more, we ﬁnd that neither FGF-2 nor Gal-1 does induce plas-
ma membrane blebbing and that an inhibitor of plasma
membrane blebbing does not have any impact on their secre-
tion eﬃciencies. We conclude that neither FGF-2 nor Gal-1
secretion is based on molecular mechanisms involving the re-
lease of membrane-bound vesicles.2. Results
2.1. FGF-2 does not induce plasma membrane blebbing
To address a potential role of plasma membrane blebbing in
unconventional protein secretion it was crucial to analyze
whether FGF-2 and Gal-1 themselves induce this type of
membrane alterations. As a positive control we used a fusion
protein of the SH4 domain of the Leishmania protein HASPB
with GFP that has recently been shown to induce extensive
membrane blebbing [21]. This was conﬁrmed by live cell imag-
ing of CHO cells employing confocal microscopy. As reported
previously [21], the HASPB-N18-GFP fusion protein induced
extensive membrane blebbing (Fig. 1, panels A/a). Corre-
sponding controls such as a palmitoylation mutant of HAS-
PB-N18-GFP (Fig. 1, panels B/b) and a construct lacking
the SH4 domain (Fig. 1, panels C/c) did not cause plasmablished by Elsevier B.V. All rights reserved.
Fig. 1. Neither FGF-2 nor Gal-1 induces plasma membrane blebbing as analyzed by live cell imaging. Cells were incubated in the presence of
doxicycline (1 lg/ml) to induce protein expression either in the absence (panels A–C; G–I) or in the presence (panels D–F; J–L) of Y-27632 (90 lM)
for 48 h at 37 C. The subcellular localization of the fusion proteins was analyzed by confocal microscopy. The lower panels show representative
surface areas of cells from each experimental condition at high magniﬁcation. The labeling of the panels in small letters and their arrangement
correspond to the upper panels (labeled in capital letters).
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also did not display any plasma membrane blebbing (Fig. 1,
panels G/g) even though these cells secrete substantial amounts
of Gal-1 [13,19,20]. Two types of FGF-2-GFP fusion proteins
were used, one without and one containing a C-terminal nucle-
ar export signal (NES). The latter one was used to increase the
cytoplamic pool of the FGF-2-GFP fusion protein. Strikingly,
neither FGF-2-GFP (Fig. 1, panels H/h) nor FGF-2-GFP-
NES (Fig. 1, panels I/i) caused plasma membrane blebbing
when expressed in CHO cells.
Based on current knowledge all kinds of plasma membrane
blebs including those formed during the induction of apoptosis
or necrosis depend on rearrangements of the cortical cytoskel-
eton [22–25]. The small GTPase Rho and its regulatory factor
Rho kinase (Rock) have been shown to play a central role in
these processes [21,26–28]. Therefore, a speciﬁc inhibitor of
Rock, Y-27632 [29], can be used to generally block the forma-tion of plasma membrane blebs [21,26–28]. To further charac-
terize the cell lines analyzed in Fig. 1, cells were treated with Y-
27632 to monitor potential changes in cell-surface morphol-
ogy. Importantly, treatment of cells with Y-27632 did not
change the subcellular distribution of any of the fusion pro-
teins being analyzed (Fig. 1). Consistent with our previous re-
sults [21], the presence of Y-27632 completely abolished
HASPB-N18-GFP-induced membrane blebs (Fig. 1, compare
panels A/a and D/d). Importantly, not even subtle diﬀerences
in plasma membrane morphology could be observed for Gal-
1 (Fig. 1; panels G/g and J/j) and FGF-2 fusion proteins
(Fig. 1; panels H/h, K/k, I/i and L/l) when compared in the ab-
sence and presence of Y-27632, respectively. The combined
data shown in Fig. 1 suggest that, even though the cells being
analyzed secrete substantial amounts of both FGF-2 and
Gal-1, plasma membrane blebbing is not induced by either
one of these unconventional secretory molecules.
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does neither aﬀect FGF-2 nor Gal-1 secretion
Eﬃcient secretion of FGF-2-GFP, Gal-1-GFP and HASPB-
N18-GFP has been documented for the experimental model
systems described in Fig. 1 [6,7,9,13,19,30]. All of these fusion
proteins are not released into the extracellular space but rather
remain associated with cell surfaces. This fact allowed for the
development of FACS-based secretion assays to monitor ex-
port on a quantitative basis [7]. Based on the results shown
in Fig. 1, we made use of these assays to analyze a potential
contribution of plasma membrane blebbing and, therefore,
quantiﬁed the amounts of FGF-2 and Gal-1 on cell surfaces
in the absence and presence of the Rock inhibitor Y-27632.
As shown in Fig. 2, both the expression levels of the various
GFP fusion proteins (green bars) and the corresponding signals
for cell-surface-associated material (=secreted population; red
bars) were quantiﬁed. Values determined in cells incubated in
the absence of Y-27632 were set to 100%. Cells expressing HAS-
PB-N18-GFP in the presence of Y-27632 were characterized by
a reduction in both expression level and secretion eﬃciency by
about 50% (Fig. 2). The expression level of a palmitoylationmu-
tant of HASPB-N18-GFP was also aﬀected by Y-27632, how-
ever, both in the absence and in the presence of Y-27632, cell-
surface staining could not be observed. These data are in line
with previous studies [30,31] and indicate that Y-27632 does
not interfere speciﬁcally with export of HASPB-N18-GFP (P-
value = 0.74). By contrast, the quantitative diﬀerences in cell-
surface staining between HASPB-N18-GFP on the one hand
and the palmitoylation mutant of HASPB-N18-GFP as well
as GFP on the other hand were found to be highly signiﬁcant
(P-value < 0.0001 in both cases). As illustrated in Fig. 2, for
all other fusion proteins, the presence of Y-27632 neither had
a pronounced impact on expression levels nor on secretion eﬃ-Fig. 2. Quantitative analysis of cell-surface localization of the GFP fusion pro
six-well plates for 48 h at 37 C in the presence of doxicycline (1 lg/ml). Wh
concentration of 90 lM. Following removal of the growth medium cells were
secondary antibodies. Cells were analyzed for both total GFP and APC-deri
each individual GFP fusion protein, GFP and cell-surface-derived signals deciencies. Rather, in case of FGF-2-GFP and FGF-2-GFP-NES,
despite slightly reduced expression levels, secretion eﬃciencies
were even elevated to a moderate extent (Fig. 2;P-value = 0.039
and 0.024, respectively). In case of Gal-1-GFP, the quantiﬁca-
tion of cell-surface staining in the absence and in the presence
of Y-27632 revealed no signiﬁcant impact on Gal-1-GFP secre-
tion (P-value = 0.39). From these data, we conclude that plas-
ma membrane blebbing is not required for cell-surface
expression of both FGF-2 and Gal-1.
2.3. FGF-2 is not released from cells in membrane-bound vesicles
To challenge the conclusions made from the experiments
shown in Fig. 2, we conducted a quantitative biochemical anal-
ysis of cell culture supernatants derived from themodel cell lines
described in Fig. 1. The amounts of the various fusion proteins
detected in extracellular vesicles were then compared to cell-sur-
face-associated material. This was achieved by labeling the cell-
surface with a membrane-impermeable biotinylation reagent
followed by aﬃnity puriﬁcation using streptavidin beads
[9,13,30]. Cells were incubated in the absence and presence of
Y-27632 followed by the collection of cellular supernatants.
These were subjected to various centrifugation steps with a ﬁnal
sedimentation of membrane vesicles at 100000 · g. To discrim-
inate between protein aggregates and proteins associated with
membrane vesicles the sediments were dissolved in 40% Nyco-
denz and loaded at the bottom of a ﬂotation gradient as illus-
trated in Fig. 3, panel A. Following ultracentrifugation, the
gradient was divided into three fractions. Fraction 1 contained
ﬂoated vesicles (Fig. 3, panel B, lanes 3 and 8). Fraction 2 rep-
resented the middle part of the gradient (Fig. 3, panel B, lanes 4
and 9) between ﬂoated vesicles and the load of the gradient, the
latter one representing fraction 3 (Fig. 3, panel B, lanes 5 and
10). The input material of the experiment (Fig. 3, panel B, lanesteins indicated employing ﬂow cytometry. CHO cells were cultivated in
ere indicated, the medium was supplemented with Y-27632 at a ﬁnal
detached and decorated with anti-GFP primary and APC-conjugated
ved cell-surface ﬂuorescence using a FACSCalibur ﬂow cytometer. For
tected in the absence of Y-27632 were set to 100% (n = 3).
Fig. 3. A comparative biochemical analysis of various GFP fusion proteins in extracellular vesicles and on cell surfaces as detected by plasma
membrane biotinylation. (A) Schematic of the Nycodenz ﬂotation gradient used to purify cell-derived extracellular vesicles. (B) Western blot analysis
of cell-surface biotinylation and extracellular vesicles. Lanes 1 and 5: input (5%); lanes 2 and 6: cell-surface (50% of biotinylated material); lanes 3 and
7: ﬂoated vesicles (100%); lanes 4 and 9: intermediate fraction (100%); lanes 5 and 10: gradient load (100%). CHO cells were grown in 10 cm culture
dishes under the conditions described in Fig. 2. Where indicated the medium was supplemented with Y-27362 at a ﬁnal concentration of 90 lM.
Following removal of growth media, cells were incubated with a membrane-impermeable biotinylation reagent (0.5 mg/ml) for 30 min at 4 C. Total
cell lysates were prepared and biotinylated material was aﬃnity-puriﬁed using streptavidin beads. The corresponding cell culture supernatants were
processed as described in Section 4. The sediment of the ﬁnal 100000 · g centrifugation was subjected to a ﬂotation analysis in a Nycodenz step
gradient. As illustrated in panel A, three fractions were generated. Floated vesicles were recovered from the top fraction of the gradient. The gradient
fractions as well as input and cell-surface-associated material was analyzed by SDS–PAGE and Western blotting using anti-GFP antibodies. (C)
Quantitative analysis of the data shown in panel B using an Odyssey infrared imaging system. For all fusion proteins indicated the amount detected
on cell surfaces using plasma membrane biotinylation (red bars) was set to 100%. The amounts of fusion proteins found in the other fractions were
expressed as the relative percentage of cell-surface-associated material (n = 3).
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following biotinylation (Fig. 3, panel B, lanes 2 and 7) were
quantiﬁed along with the gradient fractions. All fractions were
analyzed by SDS–PAGE and Western blotting using anti-GFP
antibodies and an Odyssey imaging system.
Based on cell-surface biotinylation experiments and consis-
tent with earlier observations [6,7,9,13,30], substantial amounts
of FGF-2-GFP, FGF-2-GFP-NES, Gal-1-GFP and HASPB-
N18-GFP could be detected on cell surfaces. The amounts of
all tested fusions proteins being found on cell surfaces (Fig. 3,
panel B, lane 2 [in the absence ofY-27632] and lane 7 [in the pres-
ence of Y-27632]) were not aﬀected when plasma membrane
blebbing was blocked by Y-27632. In case of HASPB-N18-
GFP-expressing CHO cells, we could identify cell-derived extra-
cellular vesicles containing this fusion protein. Substantialamounts were found in both the ﬂoated vesicle fraction
(Fig. 3, panel B, lane 3) and in the 100000 · g sediment
(Fig. 3, panel B, lane 5). As evident from the quantiﬁcation of
these data (Fig. 3, panel C) the amounts of HASPB-N18-GFP
present in extracellular vesicles were signiﬁcantly reduced by
about 50% when cells were incubated in the presence of
Y-27632. These data indicate that plasma membrane blebbing
induced by HASPB-N18-GFP resulted in the release of cell-de-
rived vesicles into the cell culture supernatant. Since the corre-
sponding controls such as HASPB-N18-Dpalm-GFP and GFP
were not detectable in extracellular vesicles (Fig. 3, panels B
and C), we considered HASPB-N18-GFP as a proper positive
control to ask whether FGF-2 and Gal-1 can also be released
by plasma membrane blebbing. While both proteins expressed
as GFP fusion proteins were detectable in substantial amounts
1366 C. Seelenmeyer et al. / FEBS Letters 582 (2008) 1362–1368on cell surfaces (see above), neither FGF-2-GFP (with or with-
outNES) norGal-1-GFPwas detectable in extracellular vesicles
(Fig. 3, panels B [lanes 3 and 5, respectively] and panel C [quan-
tiﬁcation]). The combined data shown in Figs. 2 and 3 suggest
that plasma membrane blebbing concomitant with the release
of membrane vesicles is not involved in unconventional secre-
tion of FGF-2 and Gal-1.3. Discussion
Various distinct pathways of unconventional protein secre-
tion have been proposed [10]. With regard to FGF-2 export
three diﬀerent mechanisms have been implicated two of which
involve the release of membrane vesicles into the extracellular
space. In case of the non-vesicular pathway, FGF-2 release
was reported to be mediated by direct translocation across
the plasma membrane driven by a molecular trapping mecha-
nism based on cell-surface-localized HSPGs [9,11,12]. In case
of FGF-2 export, two diﬀerent mechanisms proposed to rely
on membrane vesicles were put forward. On the one hand,
plasma membrane blebbing concomitant with the release of
vesicles into the extracellular space has been proposed [14].
On the other hand, in the presence of the Epstein-barr virus
protein LMP-1, FGF-2 was reported to get externalized along
with exosomes derived from multi-vesicular bodies [17,18]. In
the current study, using a cellular model system in which eﬃ-
cient FGF-2 secretion has been demonstrated [6,7,9], we show
that FGF-2 neither induces plasma membrane blebbing nor is
FGF-2 secretion aﬀected in the presence of Y-27632, an inhib-
itor of plasma membrane blebbing. Consistently, FGF-2 can-
not be detected in extracellular vesicles when a quantitative
analysis of cellular supernatants is conducted. We conclude
that FGF-2 secretion does not involve extracellular membrane
vesicles as intermediates of this process.
A potential role for plasma membrane blebbing in FGF-2
secretion has been proposed in SK-Hep1 cells that, upon ser-
um starvation, shed vesicles containing FGF-2 [14]. This phe-
notype depends on prolonged serum starvation for about one
week followed by a serum shock to induce plasma membrane
blebbing. Even though both a quantitative analysis and con-
trols for the release of unrelated cytoplasmic proteins were
not presented, the authors concluded that bleb-derived vesicles
carrying FGF-2 represent a speciﬁc mechanism by which
FGF-2 is secreted by unconventional means [14]. In the light
of our data this conclusion does not hold since we show that
cells eﬃciently secrete FGF-2 in the absence of plasma mem-
brane blebbing. At this point it seems likely that the ﬁndings
of Taverna et al. [14] are related to the induction of apoptosis,
a process that is known to be triggered by serum deprivation
[32,33]. Taverna and colleagues claim that FGF-2 vesicles
being shed into the cell culture supernatant are not derived
from apoptotic cells, however, it has been shown that FGF-2
can block certain stages in the progression of apoptotic pro-
grams [34]. Finally, Taverna et al. were able to use Annexin
V-coupled beads to purify these vesicles [14], i.e. they present
phosphatidylserine on their surfaces. This observation also
supports the conclusion that bleb-derived vesicles originate
from cells in which apoptosis was induced and, therefore, do
not appear to be relevant under physiological conditions.
Another pathway of vesicle-mediated release of FGF-2 has
been proposed. The initial ﬁnding was that the Epstein-barrvirus protein LMP-1 can induce both expression and secretion
of FGF-2 [17].More recently, the authors extended these studies
providing evidence that, in the presence of LMP-1, FGF-2 gets
sorted into internal vesicles of multi-vesicular bodies [18]. They
further detected FGF-2 in extracellular vesicles termed exo-
somes. At this point it is not clear what the physiological rele-
vance of these ﬁndings is since the authors use a model system
in which FGF-2 is not secreted at all when LMP-1 is absent.
Additionally, the amounts of FGF-2 being found in exosomes
were not comparedwith those being associatedwith cell surfaces
in well-established model systems such as CHO cells [6,7,9].
In case of Gal-1, early studies proposed plasma membrane
blebbing as a potential mechanism of secretion occuring dur-
ing the diﬀerentiation of myoblasts resulting in myotubes
[35]. As opposed to other model systems in which secreted
Gal-1 is retained on cell surfaces [13,19], myotubes release
Gal-1 into the medium [35]. Based on the data in this study,
the induction of plasma membrane blebs by Gal-1 in myotubes
cannot be seen in CHO cells, even though they eﬃciently ex-
port Gal-1 [13,19,20]. One possible explanation of these dis-
crepancies might be diﬀerences in cell processing for imaging.
In the studies by Cooper et al. [35], cells were ﬁxed prior to
analysis, a treatment that has been shown to cause membrane
blebs and release of vesicles into the extracellular space [36]. In
the current study, Gal-1 expressing cells were analyzed by live
cell imaging and Gal-1 induced plasma membrane blebbing
was undetectable. It is, therefore, not clear whether plasma
membrane blebbing observed in ﬁxed cells is related to physi-
ologically relevant processes.
In the current study, we have demonstrated that neither
FGF-2 nor Gal-1 induce plasma membrane blebbing. Further-
more, we do not ﬁnd detectable amounts of both proteins in
extracellular membrane vesicles. Finally, a general block of
plasma membrane blebbing caused by the Rho kinase inhibitor
Y-27632 does neither aﬀect FGF-2 nor Gal-1 secretion. From
the combined data, we conclude that eﬃcient secretion of
FGF-2 and Gal-1 is neither mediated by plasma membrane
blebbing nor by the release of exosomes derived from multi-
vesicular bodies.4. Materials and methods
4.1. Antibodies and cell lines
For detection of GFP fusion proteins in ﬂow cytometry and in Wes-
tern blotting, aﬃnity-puriﬁed polyclonal rabbit anti-GFP antibodies
were used [7]. Secondary antibodies for ﬂow cytometry (goat anti-rab-
bit APC) and for quantitative Western blot analyses (goat anti-rabbit
Alexa Fluor 680) were purchased from Invitrogen. CHO cell express-
ing the fusion proteins indicated were cultivated according to standard
procedures. To induce protein expression cells were incubated in the
presence of 1 lg/ml doxycycline for 48 h at 37 C. Where indicated,
the medium was supplemented with the Rock inhibitor Y-27632 (Cal-
biochem) at a ﬁnal concentration of 90 lM [21].
4.2. Confocal microscopy
CHO cells were grown on glass coverslips (MatTek Corp., Ashland,
USA), processed for live cell imaging and viewed with a Zeiss LSM 510
confocal microscope.
4.3. Quantitative analysis of cell-surface localization using ﬂow
cytometry
CHO cells were cultivated in six-well plates and grown to a conﬂu-
ency of about 70%. After removal of the cell culture supernatants, cells
were washed with PBS and detached using cell dissociation buﬀer (Life
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with anti-GFP primary (1 h, 4 C) and APC-conjugated secondary
antibodies (30 min, 4 C). Subsequently, cells were analyzed for total
GFP ﬂuorescence and APC-derived cell-surface ﬂuorescence using a
FACSCalibur ﬂow cytometer (BD Biosciences). Damaged cells were
identiﬁed by propidium iodide staining and excluded from the analysis.
4.4. Puriﬁcation and quantitative analysis of cell-derived extracellular
vesicles
The CHO cell lines described in Fig. 1 were cultivated in 10 cm plates
and grown to a conﬂuency of about 70%. The media were collected and
subjected to a low speed centrifugation (1000 · g, 20 min, 4 C) to re-
move detached cells. The resulting supernatant was centrifuged at
100000 · g and 4 C for 1 h to sediment membrane vesicles. To discrim-
inate between protein aggregates and proteins associated with mem-
brane vesicles, the sediments were ﬂoated in a Nycodenz step gradient.
Sediments were resuspended in 150 ll reconstitution buﬀer (25 mM
Hepes–KOH, pH 7.4, 100 mM KCl, 10% (w/v) sucrose, 1 mM DTT,
supplemented with a protease inhibitor cocktail [Roche]). They were
then combinedwith 150 ll, 80% (w/v) Nycodenz dissolved in reconstitu-
tion buﬀer to yield a 40% Nycodenz loading fraction. Samples were
transferred into SW55 ultraclear centrifuge tubes (Beckman) and over-
laid with 250 ll of a 30% (w/v) Nycodenz solution followed by 50 ll of
reconstitution buﬀer. Following centrifugation at 218000 · g for 4 h at
4 C, three fractions were recovered as illustrated in Fig. 3, panel A. Pro-
teins present in these fractions were TCA-precipitated and subjected to
SDS–PAGE. As shown in Fig. 3, panel C, following Western blotting
using anti-GFP primary and Alexa Fluor 680-conjugated secondary
antibodies, quantiﬁcation of the fusion proteins in question was per-
formed using a LI-COR Odyssey infrared imaging system.
4.5. Quantitative analysis cell-surface localization employing plasma
membrane biotinylation
After removal of cell culture media, the CHO cell lines described in
Fig. 1 were subjected to cell-surface biotinylation as described previ-
ously [9,13]. Brieﬂy, cells were washed twice with PBS supplemented
with MgCl2 (1 mM) and CaCl2 (0.1 mM) and incubated with a mem-
brane-impermeable biotinylation reagent (EZ-Link Sulfo-NHS-SS-
Biotin; Pierce, Rockford, IL) used at a ﬁnal concentration of 0.5 mg/
ml. Following quenching and an additional washing step, total cell ly-
sate was prepared using a detergent-containing buﬀer. Subsequently,
biotinylated and non-biotinylated proteins were separated employing
streptavidin beads and analyzed by SDS–PAGE followed by Western
blotting as described above.
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